These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36306645)

  • 1. rM2e-ΔPly protein immunization induces protection against influenza viruses and its co-infection with Streptococcus pneumoniae in mice.
    Guo T; Xiao J; Li L; Xu W; Yuan Y; Yin Y; Zhang X
    Mol Immunol; 2022 Dec; 152():86-96. PubMed ID: 36306645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ΔA146Ply-HA stem protein immunization protects mice against influenza A virus infection and co-infection with Streptococcus pneumoniae.
    Li L; Guo T; Yuan Y; Xiao J; Yang R; Wang H; Xu W; Yin Y; Zhang X
    Mol Immunol; 2023 Sep; 161():91-103. PubMed ID: 37531919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced protection of RIPK3-deficient mice against influenza by matrix protein 2 ectodomain targeted active and passive vaccination strategies.
    Oltean T; Ibanez LI; Divert T; Ysenbaert T; Van Eeckhoutte H; Goossens V; Schotsaert M; Bracke K; Schepens B; Maelfait J; Takahashi N; Saelens X; Vandenabeele P
    Cell Death Dis; 2022 Mar; 13(3):280. PubMed ID: 35351865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
    Kim EH; Park HJ; Han GY; Song MK; Pereboev A; Hong JS; Chang J; Byun YH; Seong BL; Nguyen HH
    J Virol; 2014 Sep; 88(17):9693-703. PubMed ID: 24920793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse.
    Mozdzanowska K; Zharikova D; Cudic M; Otvos L; Gerhard W
    Virol J; 2007 Oct; 4():118. PubMed ID: 17974006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
    Wang W; Huang B; Wang X; Tan W; Ruan L
    Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective efficacy of mucosal and subcutaneous immunization with DnaJ-ΔA146Ply against influenza and Streptococcus pneumoniae co-infection in mice.
    Hu Y; Liu Y; Yin Y; Zhang X
    Microbes Infect; 2021; 23(8):104813. PubMed ID: 33798714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.
    Shim BS; Choi YK; Yun CH; Lee EG; Jeon YS; Park SM; Cheon IS; Joo DH; Cho CH; Song MS; Seo SU; Byun YH; Park HJ; Poo H; Seong BL; Kim JO; Nguyen HH; Stadler K; Kim DW; Hong KJ; Czerkinsky C; Song MK
    PLoS One; 2011; 6(11):e27953. PubMed ID: 22140491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memory Th17 cell-mediated protection against lethal secondary pneumococcal pneumonia following influenza infection.
    Li Y; Yang Y; Chen D; Wang Y; Zhang X; Li W; Chen S; Wong SM; Shen M; Akerley BJ; Shen H
    mBio; 2023 Aug; 14(4):e0051923. PubMed ID: 37222516
    [No Abstract]   [Full Text] [Related]  

  • 10. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
    Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
    Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2.
    Ding P; Jin Q; Chen X; Yang S; Guo J; Xing G; Deng R; Wang A; Zhang G
    Int J Nanomedicine; 2019; 14():7533-7548. PubMed ID: 31571862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An experimental universal swine influenza a virus (IAV) vaccine candidate based on the M2 ectodomain (M2e) peptide does not provide protection against H1N1 IAV challenge in pigs.
    Opriessnig T; Gauger PC; Filippsen Favaro P; Rawal G; Magstadt DR; Digard P; Lee HM; Halbur PG
    Vaccine; 2024 Jan; 42(2):220-228. PubMed ID: 38087714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes.
    Wibowo N; Hughes FK; Fairmaid EJ; Lua LH; Brown LE; Middelberg AP
    Vaccine; 2014 Jun; 32(29):3651-5. PubMed ID: 24795225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting M2e to DEC-205 induces an enhanced serum antibody-dependent heterosubtypic protection against influenza A virus infection.
    Padilla-Quirarte HO; Badillo-Godinez O; Gutierrez-Xicotencatl L; Acevedo-Betancur Y; Luna-Andon JD; Montiel-Hernandez JL; Lopez-Guerrero DV; Esquivel-Guadarrama F
    Vaccine; 2019 May; 37(19):2624-2633. PubMed ID: 30955979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
    Dabaghian M; Latifi AM; Tebianian M; Dabaghian F; Ebrahimi SM
    Antiviral Res; 2015 Aug; 120():23-31. PubMed ID: 25989418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
    Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
    PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.
    Hashemi H; Pouyanfard S; Bandehpour M; Noroozbabaei Z; Kazemi B; Saelens X; Mokhtari-Azad T
    PLoS One; 2012; 7(9):e45765. PubMed ID: 23029232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.
    Zhao G; Lin Y; Du L; Guan J; Sun S; Sui H; Kou Z; Chan CC; Guo Y; Jiang S; Zheng BJ; Zhou Y
    Virol J; 2010 Jan; 7():9. PubMed ID: 20082709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice.
    Rappazzo CG; Watkins HC; Guarino CM; Chau A; Lopez JL; DeLisa MP; Leifer CA; Whittaker GR; Putnam D
    Vaccine; 2016 Mar; 34(10):1252-8. PubMed ID: 26827663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.